secwatch.observer — SEC 8-K summary
======================================

Issuer:     Keenova Therapeutics plc (—)
CIK:        0001567892
Form:       8-K
Filed at:   2023-11-15T23:59:59+00:00
Accession:  0001104659-23-118395
Event type: other_material
Sentiment:  neutral
Materiality: 1.00
Item codes: 1.01, 1.02, 2.03, 3.02, 3.03, 5.01, 5.02, 5.03, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mallinckrodt emerges from Chapter 11; old equity cancelled, $1.65B new debt issued
--------------------------------------------------------------------------------

- On Nov 14, 2023, Mallinckrodt emerged from US Chapter 11 and Irish examinership under a prepackaged plan.
- All existing ordinary shares were cancelled; 19,696,335 new common shares issued: 92.3% to first-lien creditors, 7.7% to second-lien noteholders.
- Issued $871.4M in Takeback Term Loans (SOFR+7.5%/9.5%) and $778.6M in 14.75% Takeback Notes due 2028.
- Issued 1,036,649 CVRs exercisable until Nov 2027; entitles holder to cash or equity based on market price minus $99.36.
- Board resigned except CEO; David Stetson and Jon Zinman appointed as new directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1567892/000110465923118395/0001104659-23-118395-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1567892/000110465923118395/tm2330452d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-118395

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer